# Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

> **NCT00371345** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 92 (actual)

## Conditions studied

- Breast Cancer
- Metastasis

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Dasatinib 100 mg

## Key facts

- **NCT ID:** NCT00371345
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00371345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00371345, "Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00371345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*